nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—NR1H4—renal system—cervical cancer	0.0293	0.0513	CbGeAlD
Fulvestrant—ESRRA—uterine cervix—cervical cancer	0.024	0.042	CbGeAlD
Fulvestrant—EPHX2—mammalian vulva—cervical cancer	0.024	0.042	CbGeAlD
Fulvestrant—NR1H4—female reproductive system—cervical cancer	0.0235	0.0411	CbGeAlD
Fulvestrant—ESRRA—decidua—cervical cancer	0.0229	0.04	CbGeAlD
Fulvestrant—EPHX2—uterus—cervical cancer	0.0228	0.04	CbGeAlD
Fulvestrant—ESRRA—renal system—cervical cancer	0.0225	0.0393	CbGeAlD
Fulvestrant—ESRRA—endometrium—cervical cancer	0.0217	0.038	CbGeAlD
Fulvestrant—Pelvic pain—Topotecan—cervical cancer	0.0216	0.0809	CcSEcCtD
Fulvestrant—NR1H4—female gonad—cervical cancer	0.0214	0.0374	CbGeAlD
Fulvestrant—ESRRA—mammalian vulva—cervical cancer	0.021	0.0368	CbGeAlD
Fulvestrant—ESRRA—uterus—cervical cancer	0.02	0.035	CbGeAlD
Fulvestrant—EPHX2—female gonad—cervical cancer	0.0187	0.0327	CbGeAlD
Fulvestrant—EPHX2—vagina—cervical cancer	0.0186	0.0325	CbGeAlD
Fulvestrant—ESRRA—female reproductive system—cervical cancer	0.018	0.0315	CbGeAlD
Fulvestrant—ESRRA—female gonad—cervical cancer	0.0164	0.0286	CbGeAlD
Fulvestrant—ESRRA—vagina—cervical cancer	0.0163	0.0285	CbGeAlD
Fulvestrant—ESR2—epithelium—cervical cancer	0.0145	0.0254	CbGeAlD
Fulvestrant—ESR2—uterine cervix—cervical cancer	0.0144	0.0252	CbGeAlD
Fulvestrant—ESRRA—Nuclear Receptors—RARB—cervical cancer	0.0141	0.0873	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—RARB—cervical cancer	0.014	0.0864	CbGpPWpGaD
Fulvestrant—Blood bilirubin increased—Topotecan—cervical cancer	0.0139	0.052	CcSEcCtD
Fulvestrant—NR1H4—lymph node—cervical cancer	0.0137	0.0241	CbGeAlD
Fulvestrant—Bone pain—Topotecan—cervical cancer	0.0137	0.0514	CcSEcCtD
Fulvestrant—ESR2—renal system—cervical cancer	0.0135	0.0236	CbGeAlD
Fulvestrant—ESR2—endometrium—cervical cancer	0.013	0.0228	CbGeAlD
Fulvestrant—EPHX2—lymph node—cervical cancer	0.012	0.021	CbGeAlD
Fulvestrant—ESR2—uterus—cervical cancer	0.012	0.021	CbGeAlD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.0113	0.0697	CbGpPWpGaD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.0113	0.0697	CbGpPWpGaD
Fulvestrant—ESRRA—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.0112	0.069	CbGpPWpGaD
Fulvestrant—ESR2—female reproductive system—cervical cancer	0.0108	0.0189	CbGeAlD
Fulvestrant—ESRRA—lymph node—cervical cancer	0.0105	0.0184	CbGeAlD
Fulvestrant—ESR1—epithelium—cervical cancer	0.00995	0.0174	CbGeAlD
Fulvestrant—ESR1—uterine cervix—cervical cancer	0.00987	0.0173	CbGeAlD
Fulvestrant—ESR2—female gonad—cervical cancer	0.00982	0.0172	CbGeAlD
Fulvestrant—ESR2—vagina—cervical cancer	0.00976	0.0171	CbGeAlD
Fulvestrant—ESR1—decidua—cervical cancer	0.0094	0.0165	CbGeAlD
Fulvestrant—ESR1—renal system—cervical cancer	0.00923	0.0162	CbGeAlD
Fulvestrant—ESR2—Nuclear Receptors—RARB—cervical cancer	0.009	0.0555	CbGpPWpGaD
Fulvestrant—ESR1—endometrium—cervical cancer	0.00892	0.0156	CbGeAlD
Fulvestrant—ESR1—uterus—cervical cancer	0.00822	0.0144	CbGeAlD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.00816	0.0504	CbGpPWpGaD
Fulvestrant—ESR1—female reproductive system—cervical cancer	0.00739	0.0129	CbGeAlD
Fulvestrant—Infestation—Topotecan—cervical cancer	0.00734	0.0275	CcSEcCtD
Fulvestrant—Infestation NOS—Topotecan—cervical cancer	0.00734	0.0275	CcSEcCtD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.00711	0.0439	CbGpPWpGaD
Fulvestrant—Sweating—Topotecan—cervical cancer	0.00704	0.0264	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Topotecan—cervical cancer	0.00694	0.026	CcSEcCtD
Fulvestrant—ESR1—female gonad—cervical cancer	0.00673	0.0118	CbGeAlD
Fulvestrant—ESR1—vagina—cervical cancer	0.00669	0.0117	CbGeAlD
Fulvestrant—Haemoglobin—Topotecan—cervical cancer	0.00662	0.0248	CcSEcCtD
Fulvestrant—Haemorrhage—Topotecan—cervical cancer	0.00659	0.0247	CcSEcCtD
Fulvestrant—Pharyngitis—Topotecan—cervical cancer	0.00654	0.0245	CcSEcCtD
Fulvestrant—ESR2—lymph node—cervical cancer	0.00631	0.0111	CbGeAlD
Fulvestrant—Angiopathy—Topotecan—cervical cancer	0.00598	0.0224	CcSEcCtD
Fulvestrant—Immune system disorder—Topotecan—cervical cancer	0.00595	0.0223	CcSEcCtD
Fulvestrant—Malnutrition—Topotecan—cervical cancer	0.00574	0.0215	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—POU4F1—cervical cancer	0.00569	0.0351	CbGpPWpGaD
Fulvestrant—Back pain—Topotecan—cervical cancer	0.00555	0.0208	CcSEcCtD
Fulvestrant—Anaemia—Topotecan—cervical cancer	0.0053	0.0199	CcSEcCtD
Fulvestrant—Angioedema—Topotecan—cervical cancer	0.00524	0.0197	CcSEcCtD
Fulvestrant—CYP3A4—renal system—cervical cancer	0.00515	0.00901	CbGeAlD
Fulvestrant—Leukopenia—Topotecan—cervical cancer	0.00513	0.0193	CcSEcCtD
Fulvestrant—Cough—Topotecan—cervical cancer	0.00501	0.0188	CcSEcCtD
Fulvestrant—Chest pain—Topotecan—cervical cancer	0.00488	0.0183	CcSEcCtD
Fulvestrant—Myalgia—Topotecan—cervical cancer	0.00488	0.0183	CcSEcCtD
Fulvestrant—Arthralgia—Topotecan—cervical cancer	0.00488	0.0183	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00485	0.0182	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—PIAS3—cervical cancer	0.00471	0.0291	CbGpPWpGaD
Fulvestrant—Infection—Topotecan—cervical cancer	0.00465	0.0174	CcSEcCtD
Fulvestrant—Nervous system disorder—Topotecan—cervical cancer	0.00459	0.0172	CcSEcCtD
Fulvestrant—Skin disorder—Topotecan—cervical cancer	0.00455	0.0171	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptors—RARB—cervical cancer	0.00454	0.028	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Topotecan—cervical cancer	0.00453	0.017	CcSEcCtD
Fulvestrant—Anorexia—Topotecan—cervical cancer	0.00446	0.0167	CcSEcCtD
Fulvestrant—ESR1—lymph node—cervical cancer	0.00432	0.00757	CbGeAlD
Fulvestrant—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00427	0.016	CcSEcCtD
Fulvestrant—Paraesthesia—Topotecan—cervical cancer	0.0042	0.0158	CcSEcCtD
Fulvestrant—Dyspnoea—Topotecan—cervical cancer	0.00417	0.0157	CcSEcCtD
Fulvestrant—CYP3A4—female reproductive system—cervical cancer	0.00413	0.00722	CbGeAlD
Fulvestrant—Dyspepsia—Topotecan—cervical cancer	0.00412	0.0155	CcSEcCtD
Fulvestrant—Decreased appetite—Topotecan—cervical cancer	0.00407	0.0153	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Topotecan—cervical cancer	0.00404	0.0152	CcSEcCtD
Fulvestrant—Fatigue—Topotecan—cervical cancer	0.00404	0.0151	CcSEcCtD
Fulvestrant—Constipation—Topotecan—cervical cancer	0.004	0.015	CcSEcCtD
Fulvestrant—Pain—Topotecan—cervical cancer	0.004	0.015	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Topotecan—cervical cancer	0.00383	0.0144	CcSEcCtD
Fulvestrant—Urticaria—Topotecan—cervical cancer	0.00372	0.0139	CcSEcCtD
Fulvestrant—Body temperature increased—Topotecan—cervical cancer	0.0037	0.0139	CcSEcCtD
Fulvestrant—Abdominal pain—Topotecan—cervical cancer	0.0037	0.0139	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.00359	0.0221	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—UBE3A—cervical cancer	0.00349	0.0216	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Topotecan—cervical cancer	0.00345	0.0129	CcSEcCtD
Fulvestrant—Asthenia—Topotecan—cervical cancer	0.00336	0.0126	CcSEcCtD
Fulvestrant—Pruritus—Topotecan—cervical cancer	0.00331	0.0124	CcSEcCtD
Fulvestrant—Diarrhoea—Topotecan—cervical cancer	0.0032	0.012	CcSEcCtD
Fulvestrant—Dizziness—Topotecan—cervical cancer	0.0031	0.0116	CcSEcCtD
Fulvestrant—Vomiting—Topotecan—cervical cancer	0.00298	0.0112	CcSEcCtD
Fulvestrant—Rash—Topotecan—cervical cancer	0.00295	0.0111	CcSEcCtD
Fulvestrant—Dermatitis—Topotecan—cervical cancer	0.00295	0.0111	CcSEcCtD
Fulvestrant—Headache—Topotecan—cervical cancer	0.00293	0.011	CcSEcCtD
Fulvestrant—Nausea—Topotecan—cervical cancer	0.00278	0.0104	CcSEcCtD
Fulvestrant—ESR1—Estrogen Receptor Pathway—STAT3—cervical cancer	0.00254	0.0157	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00247	0.0153	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—RARB—cervical cancer	0.00193	0.0119	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—HES1—cervical cancer	0.00173	0.0107	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00162	0.00998	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—HES1—cervical cancer	0.00158	0.00975	CbGpPWpGaD
Fulvestrant—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.00156	0.00961	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—RARB—cervical cancer	0.00141	0.00871	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—TERT—cervical cancer	0.00136	0.00837	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00128	0.00789	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—MTOR—cervical cancer	0.00126	0.00779	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00125	0.0077	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—RARB—cervical cancer	0.00123	0.00758	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CA9—cervical cancer	0.00106	0.00656	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—NOTCH2—cervical cancer	0.000934	0.00577	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—RARB—cervical cancer	0.000929	0.00574	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000923	0.0057	CbGpPWpGaD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—cervical cancer	0.000878	0.00542	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—MTOR—cervical cancer	0.000875	0.0054	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CA9—cervical cancer	0.00085	0.00525	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EGFR—cervical cancer	0.00084	0.00519	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CASP3—cervical cancer	0.000821	0.00507	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—NOTCH2—cervical cancer	0.000814	0.00502	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—MTOR—cervical cancer	0.000809	0.00499	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	0.000792	0.00489	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000791	0.00488	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CTNNB1—cervical cancer	0.000758	0.00468	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—TP53—cervical cancer	0.000745	0.0046	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000699	0.00431	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—RARB—cervical cancer	0.000679	0.00419	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000673	0.00416	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—FGFR3—cervical cancer	0.000654	0.00403	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—STAT3—cervical cancer	0.000625	0.00386	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CA9—cervical cancer	0.000621	0.00383	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—RARB—cervical cancer	0.000619	0.00382	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—NOTCH2—cervical cancer	0.000615	0.0038	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—cervical cancer	0.000615	0.00379	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—RARB—cervical cancer	0.000591	0.00365	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000578	0.00357	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000562	0.00347	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000534	0.00329	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—cervical cancer	0.000504	0.00311	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000504	0.00311	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000466	0.00287	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MTOR—cervical cancer	0.000462	0.00285	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MTOR—cervical cancer	0.00046	0.00284	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—NOTCH2—cervical cancer	0.00045	0.00278	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000448	0.00277	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—MTHFR—cervical cancer	0.000431	0.00266	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000425	0.00262	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00041	0.00253	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.00041	0.00253	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—NOTCH2—cervical cancer	0.000392	0.00242	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—NOTCH1—cervical cancer	0.000381	0.00235	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000352	0.00217	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—MTHFR—cervical cancer	0.000345	0.00213	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.00034	0.0021	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—cervical cancer	0.000325	0.002	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—cervical cancer	0.000323	0.00199	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TAAR6—cervical cancer	0.000309	0.00191	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—RARB—cervical cancer	0.000298	0.00184	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—NOTCH1—cervical cancer	0.000278	0.00172	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—cervical cancer	0.000273	0.00168	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000269	0.00166	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000254	0.00157	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—MTHFR—cervical cancer	0.000252	0.00156	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—NOTCH1—cervical cancer	0.000242	0.0015	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—WNT2—cervical cancer	0.000241	0.00149	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000226	0.00139	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKAP13—cervical cancer	0.000212	0.00131	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NOTCH2—cervical cancer	0.000198	0.00122	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—WNT5A—cervical cancer	0.000183	0.00113	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NOTCH2—cervical cancer	0.000128	0.000793	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—NOTCH1—cervical cancer	0.000122	0.000755	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HES1—cervical cancer	0.000105	0.00065	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TERT—cervical cancer	9.23e-05	0.00057	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA9—cervical cancer	8.89e-05	0.000549	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR3—cervical cancer	8.47e-05	0.000523	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NOTCH1—cervical cancer	7.95e-05	0.000491	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MTOR—cervical cancer	5.96e-05	0.000368	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—cervical cancer	5.48e-05	0.000338	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—cervical cancer	5.28e-05	0.000326	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—cervical cancer	4.6e-05	0.000284	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—cervical cancer	4.18e-05	0.000258	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—MTHFR—cervical cancer	3.61e-05	0.000223	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—cervical cancer	3.51e-05	0.000217	CbGpPWpGaD
